GlassScriptPhysician profile
Vivian Bethala
NPI 1235191800
$3,123.16
in general payments reported to CMS, 2019-2025
19 companies · $301 in 2025
The $301 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $695 · 2020: $220 · 2021: $335 · 2022: $407 · 2023: $714 · 2024: $451 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,465.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $755.27 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $375.36 | 2019-2023 | Trulance, Xifaxan |
| Pfizer INC. | $364.06 | 2019-2024 | |
| Abbvie INC. | $290.12 | 2019-2025 | Rinvoq, Skyrizi |
| Astrazeneca Pharmaceuticals LP | $250.00 | 2025 | Tezspire |
| Boston Scientific Corporation | $217.09 | 2019-2023 | Watchman, Spyglass, Resolution 360 Clip |
| Celgene Corporation | $132.06 | 2021-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $114.50 | 2019-2025 | Entyvio |
| Ferring Pharmaceuticals INC. | $110.94 | 2019-2023 | Rebyota |
| Optinose US, INC. | $109.88 | 2021 | |
| Allergan, INC. | $66.21 | 2019 | |
| Merck Sharp & Dohme LLC | $47.34 | 2019-2024 | Dificid |
| Janssen Biotech, INC. | $43.59 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $40.98 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $36.29 | 2024 | Dupixent |
| Madrigal Pharmaceuticals | $16.86 | 2024 | Resmetirom |
| Braintree Laboratories, INC. | $14.98 | 2019 | |
| Cardiovascular Systems INC. | $12.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivian Bethala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.